drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous TCR-T)
drug_description
Autologous, gene-modified TCR-engineered T cells (TCR-T; T-Plex) expressing a high-affinity TCR specific for MAGE-C2 peptide presented by HLA-B*07:02; recognizes peptide–HLA on tumor cells to trigger TCR/CD3 signaling and cytotoxicity following lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Transgenic
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a high-affinity TCR specific for the MAGE-C2 peptide presented by HLA-B*07:02. Binding to the peptide–HLA complex on tumor cells triggers TCR/CD3 signaling, activating the T cells to mediate cytokine release and targeted cytotoxic killing of antigen-positive tumor cells following lymphodepletion.
drug_name
TSC-201-B0702
nct_id_drug_ref
NCT05973487